Orgenesis Valuation
| ORGSDelisted Stock | USD 1.22 0.31 20.26% |
Today, the company appears to be overvalued. Orgenesis holds a recent Real Value of $1.16 per share. The prevailing price of the company is $1.22. Our model determines the value of Orgenesis from analyzing the company fundamentals such as Shares Owned By Insiders of 21.16 %, return on equity of -7.27, and Current Valuation of 23.01 M as well as examining its technical indicators and probability of bankruptcy. . In general, most investors support acquiring undervalued entities and selling overvalued entities since, at some point, asset prices and their ongoing real values will merge together.
Overvalued
Today
Please note that Orgenesis' price fluctuation is out of control at this time. Calculation of the real value of Orgenesis is based on 3 months time horizon. Increasing Orgenesis' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Orgenesis otc stock is determined by what a typical buyer is willing to pay for full or partial control of Orgenesis. Since Orgenesis is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Orgenesis OTC Stock. However, Orgenesis' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 1.22 | Real 1.16 | Hype 1.22 |
The intrinsic value of Orgenesis' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Orgenesis' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Orgenesis helps investors to forecast how Orgenesis otc stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Orgenesis more accurately as focusing exclusively on Orgenesis' fundamentals will not take into account other important factors: Orgenesis Total Value Analysis
Orgenesis is now forecasted to have valuation of 23.01 M with market capitalization of 10.07 M, debt of 22.62 M, and cash on hands of 2.3 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Orgenesis fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
23.01 M | 10.07 M | 22.62 M | 2.3 M |
Orgenesis Investor Information
About 21.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 1.26. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Orgenesis recorded a loss per share of 8.0. The entity last dividend was issued on the 16th of November 2017. The firm had 1:10 split on the 25th of September 2024. Based on the key indicators related to Orgenesis' liquidity, profitability, solvency, and operating efficiency, Orgenesis is not in a good financial situation at this time. It has a very high probability of going through financial hardship in January.Orgenesis Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Orgenesis has an asset utilization ratio of 3.64 percent. This implies that the OTC Stock is making $0.0364 for each dollar of assets. An increasing asset utilization means that Orgenesis is more efficient with each dollar of assets it utilizes for everyday operations.Orgenesis Ownership Allocation
The market capitalization of Orgenesis is $10.07 Million. Orgenesis has significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Note, that even with negative profits, if the true value of the company is larger than the current market value, you may still be able to generate positive returns on investment in this company.Orgenesis Profitability Analysis
The company reported the previous year's revenue of 530 K. Net Loss for the year was (64.92 M) with profit before overhead, payroll, taxes, and interest of 36.02 M.About Orgenesis Valuation
The otc valuation mechanism determines Orgenesis' current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Orgenesis based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Orgenesis. We calculate exposure to Orgenesis's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Orgenesis's related companies.Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland. Orgenesis operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 151 people.
8 Steps to conduct Orgenesis' Valuation Analysis
OTC Stock's valuation is the process of determining the worth of any otc stock in monetary terms. It estimates Orgenesis' potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of otc stock valuation is a single number representing a OTC Stock's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Orgenesis' valuation analysis, follow these 8 steps:- Gather financial information: Obtain Orgenesis' financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Orgenesis' revenue streams: Identify Orgenesis' primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Orgenesis' industry and market trends, including the size of the market, growth rate, and competition.
- Establish Orgenesis' growth potential: Evaluate Orgenesis' management, business model, and growth potential.
- Determine Orgenesis' financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the OTC Stock's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Orgenesis' estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Orgenesis Growth Indicators
Investing in growth stocks can be very risky. If the company such as Orgenesis does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 29 M |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in price. Note that the Orgenesis information on this page should be used as a complementary analysis to other Orgenesis' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Other Consideration for investing in Orgenesis OTC Stock
If you are still planning to invest in Orgenesis check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Orgenesis' history and understand the potential risks before investing.
| AI Portfolio Architect Use AI to generate optimal portfolios and find profitable investment opportunities | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |